Imalumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | BAX69 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Imalumab (BAX69) is an experimental monoclonal antibody against macrophage inhibitory factor (MIF), a cytokine known to exacerbate tumor growth.[1][2][3] and as of January 2017 it is being tested in Phase IIa clinical trials for metastatic colorectal cancer.[2] It was developed by Cytokine PharmaSciences and Baxalta, which was purchased by Shire Pharmaceuticals.[4]
A phase I/II trial in patients with malignant ascites was terminated in 2016.[4]
References[edit]
- ^ Douillard P, Thiele M, Schinagl A, Halama N, Jaeger D, Yazji S, Scheiflinger F, Kerschbaumer R (2015). "Abstract A153: Imalumab, a first-in-class anti-oxidized macrophage migration inhibitory factor (OxMIF) antibody penetrates tumor tissues and shows antitumor activity in patients". Therapeutic Agents: Biological. pp. A153. doi:10.1158/1535-7163.TARG-15-A153.
- ^ a b Clinical trial number NCT02448810 for "Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer" at ClinicalTrials.gov
- ^ Clinical trial number NCT01765790 for "Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumor" at ClinicalTrials.gov
- ^ a b "Imalumab". AdisInsight. Springer Nature Switzerland AG.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |